Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Prices IPO, Anticipates Net Proceeds of $113.5M

NEW YORK (GenomeWeb News) – Intrexon today said that it plans to offer more than 8.3 million shares of its stock at between $14 and $16 per share in connection to its proposed initial public offering.

The Germantown, Md.-based synthetic biology firm announced its plans to go public earlier this month, saying it hoped to raise up to $125 million. In its amended Form S-1 filed on Monday, Intrexon said that net proceeds from the offering are anticipated to be $113.5 million, based on a $15 midpoint figure on the offering's share price range.

JP Morgan and Barclays are the joint book-running agents on the offering. Intrexon plans to list on the New York Stock Exchange under ticker symbol "XON".

The company said in its SEC document that its Chairman, President, and CEO Randal Kirk, on behalf of himself and certain of his affiliates, has said he is interested in purchasing up to $30 million in aggregate of Intrexon's common stock in the public offering. At the $15 midpoint price, Kirk and the affiliates would purchase an aggregate of up to about 2 million of the 8.3 million shares in the offering, Intrexon said.

Kirk and his affiliates own about 71 percent of Intrexon as of July 15. Following the offering, he and his affiliates would control about 64 percent of the company's stock, it said.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.